Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
64.5M
-
Number of holders
-
103
-
Total 13F shares, excl. options
-
52.4M
-
Shares change
-
-2.74M
-
Total reported value, excl. options
-
$145M
-
Value change
-
-$16.3M
-
Put/Call ratio
-
1.96
-
Number of buys
-
60
-
Number of sells
-
-36
-
Price
-
$2.77
Significant Holders of Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) as of Q4 2024
125 filings reported holding INZY - Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share as of Q4 2024.
Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) has 103 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 52.4M shares
of 64.5M outstanding shares and own 81.21% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (5.16M shares), Pivotal bioVenture Partners Investment Advisor LLC (4.49M shares), Sofinnova Investments, Inc. (4.28M shares), Affinity Asset Advisors, LLC (3.97M shares), Rock Springs Capital Management LP (3.86M shares), BlackRock, Inc. (3.81M shares), VANGUARD GROUP INC (2.63M shares), NEA Management Company, LLC (2.44M shares), EVENTIDE ASSET MANAGEMENT, LLC (2.22M shares), and MILLENNIUM MANAGEMENT LLC (1.88M shares).
This table shows the top 103 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.